DNA Analytics

Executive Summary

DNA Analytics is a San Diego-based biotechnology company leveraging artificial intelligence and statistical algorithms to optimize the design of gene probes for therapies, vaccines, and diagnostics. Its core platform, AccuMatch™, accurately predicts the melting temperature of chemically modified nucleic acid probes, enabling researchers to accelerate development and reduce costs. The company targets genetic medicines for cancer, neurological, hepatological, retinal, and rare genetic diseases. Founded in 2015, DNA Analytics operates as a private entity with a focus on enabling more effective genetic therapies through precision probe design. The company's technology addresses a critical bottleneck in nucleic acid-based drug development—designing probes with high binding specificity and affinity. By improving the accuracy of melting temperature predictions, AccuMatch™ aims to reduce trial-and-error in probe selection, potentially shortening development timelines and lowering costs. While DNA Analytics has not disclosed funding or valuation, its platform could see adoption by pharmaceutical and diagnostic companies. Key upcoming catalysts include potential Series A financing, strategic partnerships with gene therapy developers, and the launch of enhanced platform features to expand its user base.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round60% success
• Q2 2026Strategic Partnership with a Gene Therapy Developer50% success
• Q4 2026Release of AccuMatch™ Platform Update with Expanded Capabilities70% success